Green Elephant Biotech has introduced Archimedes One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the market ahead of its planned commercial launch later this year.

Archimedes One was developed to address a central challenge in cell therapy manufacturing: how to scale adherent cell processes without compromising biology or introducing unnecessary complexity.

Instead of forcing adherent cells into suspension or complex matrices, the system enables controlled, perfusion-based adherent culture with integrated process monitoring and automated harvesting. It is compatible with standard biocontrollers for parameters such as pH, dissolved oxygen, and temperature, and does not require conditioning vessels or custom subsystems. The system is designed to combine the familiarity of 2D culture with the control of a bioreactor. Automated and standardized harvesting replaces manual detachment steps, supporting improved reproducibility and a clearer path toward GMP manufacturing and tech transfer between sites.

“Cell therapy manufacturing should not require choosing between biological integrity and industrial scalability,” said Joel Eichmann, Co-Founder of Green Elephant Biotech. “With Archimedes One, we are introducing a platform that aligns process control with adherent cell biology and reduces operational complexity.”

Alongside the market introduction, Green Elephant Biotech is opening an Early Access Program for selected cell therapy companies and CDMOs. Participants will gain early access to production units, receive dedicated technical support, and have the opportunity to contribute to application data and case studies ahead of the commercial launch.